Patents Assigned to Celtrix Pharmaceuticals
  • Patent number: 5824467
    Abstract: Methods are provided for formulating models for predicting whether subjects will respond to a particular drug or treatment regimen. Biochemical profiles are obtained (by measuring a variety or biochemical parameters) for a test group before and after treatment with the drug or regimen. These values are used formulate a specific predictive method for the particular drug or treatment regimen. The predictive measurement is then used with biochemical parameters obtained from a subject to predict whether that subject will respond to the particular drug or treatment regimen.
    Type: Grant
    Filed: February 25, 1997
    Date of Patent: October 20, 1998
    Assignee: Celtrix Pharmaceuticals
    Inventor: Desmond Mascarenhas
  • Patent number: 5527776
    Abstract: This invention includes a method of treating subjects with immunologic and hematologic disorders, such as immune deficiencies and anemias characterized by deficient total hemoglobin. The treatment includes administering to the subject insulin-like growth factor binding protein-3 (IGFBP-3), alone or in a complex including an insulin-like growth factor (IGF), in an amount sufficient to improve the immunologic and/or hematologic disorder, for example, increasing the level of total hemoglobin or improving immune deficiencies, such as occur post-chemotherapy. Another aspect of the invention includes administering IGFBP-3 alone to treat IGF-driven lymphoproliferative conditions, such as leukemias, inflammatory skin diseases, and nasal polyps.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: June 18, 1996
    Assignee: Celtrix Pharmaceuticals
    Inventors: Joseph A. Carlino, Howard R. Higley, Christopher A. Maack